FDA announces new Drug Safety Initiative. So what’s next?

Here at SRxA we’re thrilled to hear that the FDA is exploring the use of cutting-edge technology to help study and better understand adverse events.  Last week, Biovista Inc, announced that the FDA has licensed its advanced technology platform that is able to cross-correlate thousands of adverse events against any drug or combination therapy.  Ultimately, it’s hoped that this technology will enable physicians to predict which patients are likely to suffer side effects from a particular drug and thus make prescribing safer for patients.

After embracing this space-age technology we hope that the Agency will soon come to a decision about other  space-age media.  You, our readers, may have already heard of them: the Internet, the Blogosphere and Social Media!

Our team of certified Social Media Strategists is standing by!